Shanghai Junshi Biosciences Co., Ltd.

1877

CNE100003FF7

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 09:08:42 28/06/2024 BST			5-day change	1st Jan Change
11.7 ^HKD	-0.51%		+3.72%	-39.81%

06-26	Shanghai Junshi Biosciences Breast Cancer Drug Obtains DRC from NMPA; Shares Jump 8%	MT
06-25	Shanghai Junshi Biosciences Co., Ltd. Receives the Drug Registration Certificate Issued by the National Medical Products Administration	CI

Shanghai Junshi Biosciences Co., Ltd. Provides Earnings Guidance for the Six Months Ending 30 June 2020

May 22, 2020 at 02:25 pm

Shanghai Junshi Biosciences Co., Ltd. provided earnings guidance for the six months ending 30 June 2020. For the period, the company expects operating income in the range of RMB 455,723,100 to RMB 560,723,100. Net loss to be in the range of RMB 681,329,900 to RMB 563,434,300.

Latest news about Shanghai Junshi Biosciences Co., Ltd.

Shanghai Junshi Biosciences Breast Cancer Drug Obtains DRC from NMPA; Shares Jump 8%	06-26	MT
Shanghai Junshi Biosciences Co., Ltd. Receives the Drug Registration Certificate Issued by the National Medical Products Administration	06-25	CI
Shanghai Junshi Biosciences Co., Ltd. Announces Board Changes	06-21	CI
Shanghai Junshi Biosciences Co., Ltd Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Small Cell Lung Cancer	06-18	CI
Junshi Biosciences' Cancer Drug Gets Registration Certificate from Chinese Regulator	06-13	MT
Shanghai Junshi Biosciences Co., Ltd. Receives Drug Registration Certificate Issued by the National Medical Products Administration	06-12	CI
Junshi Bio Achieves Primary Endpoints in Phase 3 Trial of Liver Cancer Treatment	06-12	MT
Shanghai Junshi Biosciences Cancer Drug Shows Positive Phase III Trial Results	06-12	MT
Shanghai Junshi Biosciences Co., Ltd. Announces Phase III Clinical Study of Toripalimab in Combination with Bevacizumab for the First-Line Treatment of Advanced Hepatocellular Carcinoma	06-11	CI
Shanghai Junshi Biosciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-29	CI
Shanghai Junshi Biosciences Receives Hong Kong Approval for Cancer Drug Toripalimab	04-25	MT
Shanghai Junshi Biosciences Co., Ltd. Receives Notice from the Drug Office, Department of Health, the Government of the Hong Kong Special Administration Region	04-24	CI
Shanghai Junshi Biosciences Co., Ltd. Announces Executive Changes	04-24	CI
Junshi Biosciences Gets Nod to Register Toripalimab Injection	04-08	MT
Shanghai Junshi Biosciences Co., Ltd. Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer	04-07	CI
Shanghai Junshi Biosciences Supplemental NDA for Lipid Drug Accepted by NMPA	04-03	MT
Shanghai Junshi Biosciences Co., Ltd. Announces the Acceptance of the Supplemental New Drug Applications for Ongericimab Injection	04-02	CI
Tranche Update on Shanghai Junshi Biosciences Co., Ltd.'s Equity Buyback Plan announced on September 10, 2023.	04-01	CI
Shanghai Junshi Biosciences' Loss Narrows in 2023, Misses Estimates	03-29	MT
Junshi Bio's 2023 Loss Widens, Misses Estimates	02-26	MT
Shanghai Junshi Biosciences Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	02-23	CI
Junshi Biosciences Proposes Share Buyback	02-02	MT
Junshi Says NDA for Anti-Cancer Drug Accepted By Singapore's HSA	02-01	MT
Shanghai Junshi Biosciences Co., Ltd. Announces Acceptation of New Drug Application of Toripalimab by Singapore Health Sciences Authority	02-01	CI
Shanghai Junshi Biosciences to Narrow Losses	01-31	MT

Chart Shanghai Junshi Biosciences Co., Ltd.

Duration

Period

Chart Shanghai Junshi Biosciences Co., Ltd.

More charts

Company Profile

Shanghai Junshi Biosciences Co Ltd is a China-based company mainly engaged in innovation-driven biopharmaceutical business. The Company's main businesses are the discovery, clinical research and development of innovative drugs. The Company's main products include teriprizumab injection, Etesevimab, adalimumab injection and other drugs, which are used to treat malignant tumors, autoimmune system diseases, chronic metabolic diseases, nervous system diseases and infectious diseases . The Company is also engaged in the clinical research and development of recombinant humanized anti-PCSK9 monoclonal antibody injection and other drugs. The Company provides its products for domestic and overseas markets.

Sector

Pharmaceuticals

Calendar

28/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Shanghai Junshi Biosciences Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

10.89 CNY

Average target price

16.09 CNY

Spread / Average Target

+47.79%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
SHANGHAI JUNSHI BIOSCIENCES CO., LTD.	-39.81%	3.39B
CSL LIMITED	+2.08%	95.18B
SAMSUNG BIOLOGICS CO.,LTD.	-4.34%	37.55B
BIOGEN INC.	-10.41%	33.75B
UCB	+77.63%	28.2B
BIOMARIN PHARMACEUTICAL INC.	-14.61%	15.63B
INCYTE CORPORATION	-3.46%	13.63B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.31%	11.5B
ALTEOGEN INC.	+184.77%	10.81B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-54.13%	9.23B

Biopharmaceuticals